Targeting protein Kinase C downstream of growth factor and adhesion signalling

Cancers

Volumn 7, Issue 3, 2015, Pages 1271-1291

  Dowling, Catríona M ^a   Kiely, Patrick A ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Cell adhesion.; Cell proliferation; G protein coupled receptors; Growth factor signaling; Integrins; Protein Kinase C; Receptor tyrosine kinase

Indexed keywords

BRYOSTATIN; ENZASTAURIN; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; INTEGRIN; MIDOSTAURIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RECEPTOR FOR ACTIVATED C KINASE 1;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BINDING SITE; BRAIN CANCER; CALCIUM CELL LEVEL; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DIMERIZATION; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; HUMAN; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW;

EID: 84937433554     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7030836     Document Type: Review

References (161)

1. Mouw, J. K.; Ou, G.; Weaver, V. M. Extracellular matrix assembly: A multiscale deconstruction. Nat. Rev. Mol. Cell Biol. 2014, 15, 771-785. [CrossRef] [PubMed].
2. Kim, S.-H.; Turnbull, J.; Guimond, S. Extracellular matrix and cell signalling: The dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 2011, 209, 139-151. [CrossRef] [PubMed].
3. Mecham, R. P. Overview of extracellular matrix. In Current Protocols in Cell Biology; JohnWiley & Sons, Inc.: Hoboken, NJ, USA, 2012; Volume 10.
4. Lu, P.; Weaver, V. M.; Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012, 196, 395-406. [CrossRef] [PubMed].
5. Lemmon, M. A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117-1134. [CrossRef] [PubMed].
6. Venkatakrishnan, A.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors. Nature 2013, 494, 185-194. [CrossRef] [PubMed].
7. Seguin, L.; Desgrosellier, J. S.; Weis, S. M.; Cheresh, D. A. Integrins and cancer: Regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015, 25, 234-240. [CrossRef] [PubMed].
8. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225. [CrossRef].
9. Gschwind, A.; Fischer, O. M.; Ullrich, A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 2004, 4, 361-370. [CrossRef] [PubMed].
10. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212. [CrossRef].
11. Campbell, I. D.; Humphries, M. J. Integrin structure, activation, and interactions. Cold Spring Harb Perspect. Biol. 2011, 3. [CrossRef] [PubMed].
12. Humphries, J. D.; Byron, A.; Humphries, M. J. Integrin ligands at a glance. J. Cell Sci. 2006, 119, 3901-3903. [CrossRef] [PubMed].
13. Huttenlocher, A.; Horwitz, A. R. Integrins in cell migration. Cold Spring Harb Perspect. Biol. 2011, 3, a005074. [CrossRef] [PubMed].
14. Pawson, T.; Scott, J. D. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997, 278, 2075-2080. [CrossRef] [PubMed].
15. Reiser, J.; Sever, S.; Faul, C. Signal transduction in podocytes[mdash]spotlight on receptor tyrosine kinases. Nat. Rev. Nephrol. 2014, 10, 104-115. [CrossRef] [PubMed].
16. Park, J. B.; Lee, C. S.; Jang, J.-H.; Ghim, J.; Kim, Y.-J.; You, S.; Hwang, D.; Suh, P.-G.; Ryu, S. H. Phospholipase signalling networks in cancer. Nat. Rev. Cancer 2012, 12, 782-792. [CrossRef] [PubMed].
17. Marshall, C. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80, 179-185. [CrossRef].
18. Plopper, G. E.; McNamee, H. P.; Dike, L. E.; Bojanowski, K.; Ingber, D. E. Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. Mol. Biol. Cell 1995, 6, 1349-1365. [CrossRef] [PubMed].
19. Yamada, K. M.; Miyamoto, S. Integrin transmembrane signaling and cytoskeletal control. Curr. Opin. Cell Biol. 1995, 7, 681-689. [CrossRef].
20. Zhao, X.; Guan, J.-L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 2011, 63, 610-615. [CrossRef] [PubMed].
21. Adams, D. R.; Ron, D.; Kiely, P. A. Rack1, a multifaceted scaffolding protein: Structure and function. Cell Commun. Signal 2011, 9, 22. [CrossRef] [PubMed].
22. Dwane, S.; Durack, E.; O'Connor, R.; Kiely, P. A. Rack1 promotes neurite outgrowth by scaffolding agap2 to fak. Cell. Signal 2014, 26, 9-18. [CrossRef] [PubMed].
23. Kiely, P. A.; Baillie, G. S.; Barrett, R.; Buckley, D. A.; Adams, D. R.; Houslay, M. D.; O'Connor, R. Phosphorylation of rack1 on tyrosine 52 by c-abl is required for insulin-like growth factor i-mediated regulation of focal adhesion kinase. J. Biol. Chem. 2009, 284, 20263-20274. [CrossRef] [PubMed].
24. Kiely, P. A.; Baillie, G. S.; Lynch, M. J.; Houslay, M. D.; O'Connor, R. Tyrosine 302 in rack1 is essential for insulin-like growth factor-i-mediated competitive binding of pp2a and beta1 integrin and for tumor cell proliferation and migration. J. Biol. Chem. 2008, 283, 22952-22961. [CrossRef] [PubMed].
25. Kiely, P. A.; Leahy, M.; O'Gorman, D.; O'Connor, R. Rack1-mediated integration of adhesion and insulin-like growth factor I (IGF-I) signaling and cell migration are defective in cells expressing an IGF-I receptor mutated at tyrosines 1250 and 1251. J. Biol. Chem. 2005, 280, 7624-7633. [CrossRef] [PubMed].
26. Kiely, P. A.; O'Gorman, D.; Luong, K.; Ron, D.; O'Connor, R. Insulin-like growth factor i controls a mutually exclusive association of rack1 with protein phosphatase 2a and +1 integrin to promote cell migration. Mol. Cell. Biol. 2006, 26, 4041-4051. [CrossRef] [PubMed].
27. Kiely, P. A.; Sant, A.; O'Connor, R. Rack1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated akt activation and protection from cell death. J. Biol. Chem. 2002, 277, 22581-22589. [CrossRef] [PubMed].
28. O'Donovan, H. C.; Kiely, P. A.; O'Connor, R. Effects of rack1 on cell migration and IGF-I signalling in cardiomyoctes are not dependent on an association with the IGF-IR. Cell. Signal 2007, 19, 2588-2595. [CrossRef] [PubMed].
29. Zeng, L.; Webster, S.; Newton, P. The biology of protein kinase C. In Calcium Signaling; Islam, M. S., Ed.; Springer: Dordrecht, The Netherlands, 2012; Volume 740, pp. 639-661.
30. Newton, A. C. Protein kinase C: Structure, function, and regulation. J. Biol. Chem. 1995, 270, 28495-28498. [CrossRef] [PubMed].
31. Newton, A. C. Protein kinase C: Poised to signal. Am. J. Physiol. Endocrinol. Metab. 2010, 298, E395-E402. [CrossRef] [PubMed].
32. Bosco, R.; Melloni, E.; Celeghini, C.; Rimondi, E.; Vaccarezza, M.; Zauli, G. Fine tuning of protein kinase C (PKC) isoforms in cancer: Shortening the distance from the laboratory to the bedside. Mini Rev. Med. Chem. 2011, 11, 185-199. [CrossRef] [PubMed].
33. Mochly-Rosen, D.; Das, K.; Grimes, K. V. Protein kinase C, an elusive therapeutic target? Nat. Rev. Drug Discov. 2012, 11, 937-957. [CrossRef] [PubMed].
34. Ohno, S.; Nishizuka, Y. Protein kinase C isotypes and their specific functions: Prologue. J. Biochem. 2002, 132, 509-511. [CrossRef] [PubMed].
35. Fogh, B. S.; Multhaupt, H. A. B.; Couchman, J. R. Protein kinase C, focal adhesions and the regulation of cell migration. J. Histochem. Cytochem. 2014, 62, 172-184. [CrossRef] [PubMed].
36. Mellor, H.; Parker, P. The extended protein kinase C superfamily. Biochem. J. 1998, 332, 281-292. [PubMed].
37. Martiny-Baron, G.; Fabbro, D. Classical PKC isoforms in cancer. Pharmacol. Res. 2007, 55, 477-486. [CrossRef] [PubMed].
38. Poli, A.; Mongiorgi, S.; Cocco, L.; Follo, M. Y. Protein kinase C involvement in cell cycle modulation. Biochem. Soc. Trans. 2014, 42, 1471-1476. [CrossRef] [PubMed].
39. Defilippi, P.; Venturino, M.; Gulino, D.; Duperray, A.; Boquet, P.; Fiorentini, C.; Volpe, G.; Palmieri, M.; Silengo, L.; Tarone, G. Dissection of pathways implicated in integrin-mediated actin cytoskeleton assembly involvement of protein kinase C, RHO GTPASE, and tyrosine phosphorylation. J. Biol. Chem. 1997, 272, 21726-21734. [CrossRef] [PubMed].
40. Huang, X.; Wu, J.; Spong, S.; Sheppard, D. The integrin alphavbeta6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J. Cell Sci. 1998, 111, 2189-2195. [PubMed].
41. Bordeleau, F.; Galarneau, L.; Gilbert, S.; Loranger, A.; Marceau, N. Keratin 8/18 modulation of protein kinase C-mediated integrin-dependent adhesion and migration of liver epithelial cells. Mol. Biol. Cell 2010, 21, 1698-1713. [CrossRef] [PubMed].
42. Gonelli, A.; Mischiati, C.; Guerrini, R.; Voltan, R.; Salvadori, S.; Zauli, G. Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev. Med. Chem. 2009, 9, 498-509. [CrossRef] [PubMed].
43. Zhang, W.; Zong, C. S.; Hermanto, U.; Lopez-Bergami, P.; Ronai, Z. E.; Wang, L.-H. Rack1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Mol. Cell. Biol. 2006, 26, 413-424. [CrossRef] [PubMed].
44. Haimovich, B.; Kaneshiki, N.; Ji, P. Protein kinase C regulates tyrosine phosphorylation of PP125FAK in platelets adherent to fibrinogen. Blood 1996, 87, 152-161. [PubMed].
45. Steinberg, S. F. Structural basis of protein kinase C isoform function. Physiol. Rev. 2008, 88, 1341-1378. [CrossRef] [PubMed].
46. Rosse, C.; Linch, M.; Kermorgant, S.; Cameron, A. J. M.; Boeckeler, K.; Parker, P. J. PKC and the control of localized signal dynamics. Nat. Rev. Mol. Cell. Biol. 2010, 11, 103-112. [CrossRef] [PubMed].
47. Antal, C. E.; Violin, J. D.; Kunkel, M. T.; Skovsãÿ, S.; Newton, A. C. Intramolecular conformational changes optimize protein kinase C signaling. Chem. Biol. 2014, 21, 459-469. [CrossRef] [PubMed].
48. Colãşn-Gonzãąlez, F.; Kazanietz, M. G. C1 domains exposed: From diacylglycerol binding to protein-protein interactions. Biochim. Biophys. Acta 2006, 1761, 827-837. [CrossRef] [PubMed].
49. Cho, W. Membrane targeting by C1 and C2 domains. J. Biol. Chem. 2001, 276, 32407-32410. [CrossRef] [PubMed].
50. Ananthanarayanan, B.; Stahelin, R. V.; Digman, M. A.; Cho, W. Activation mechanisms of conventional protein kinase C isoforms are determined by the ligand affinity and conformational flexibility of their C1 domains. J. Biol. Chem. 2003, 278, 46886-46894. [CrossRef] [PubMed].
51. Stahelin, R. V. Ready, set, go! How protein kinase c manages dynamic signaling. Chem. Biol. 2014, 21, 433-434. [CrossRef] [PubMed].
52. Oancea, E.; Meyer, T. Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals. Cell 1998, 95, 307-318. [CrossRef].
53. Newton, A. Regulation of the abc kinases by phosphorylation: Protein kinase C as a paradigm. Biochem. J. 2003, 370, 361-371. [CrossRef] [PubMed].
54. Messerschmidt, A.; Macieira, S.; Velarde, M.; Bãddeker, M.; Benda, C.; Jestel, A.; Brandstetter, H.; Neuefeind, T.; Blaesse, M. Crystal structure of the catalytic domain of human atypical protein kinase C-IOTA reveals interaction mode of phosphorylation site in turn motif. J. Mol. Biol. 2005, 352, 918-931. [CrossRef] [PubMed].
55. Seki, T.; Matsubayashi, H.; Amano, T.; Shirai, Y.; Saito, N.; Sakai, N. Phosphorylation of PKC activation loop plays an important role in receptor-mediated translocation of PKC. Genes Cells 2005, 10, 225-239. [CrossRef] [PubMed].
56. Dutil, E. M.; Newton, A. C. Dual role of pseudosubstrate in the coordinated regulation of protein kinase C by phosphorylation and diacylglycerol. J. Biol. Chem. 2000, 275, 10697-10701. [CrossRef] [PubMed].
57. Hauge, C.; Antal, T. L.; Hirschberg, D.; Doehn, U.; Thorup, K.; Idrissova, L.; Hansen, K.; Jensen, O. N.; Jãÿrgensen, T. J.; Biondi, R. M. Mechanism for activation of the growth factor-activated AGC kinases by turn motif phosphorylation. EMBO J. 2007, 26, 2251-2261. [CrossRef] [PubMed].
58. Behn-Krappa, A.; Newton, A. C. The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr. Biol. 1999, 9, 728-737. [CrossRef].
59. Oliva, J. L.; Griner, E. M.; Kazanietz, M. G. PKC isozymes and diacylglycerol-regulated proteins as effectors of growth factor receptors. Growth Factors 2005, 23, 245-252. [CrossRef] [PubMed].
60. Smith, M. R.; DeGudicibus, S. J.; Stacey, D. W. Requirement for C-RAS proteins during viral oncogene transformation. Nature 1986, 320, 540-543. [CrossRef] [PubMed].
61. Margolis, B.; Rhee, S.; Felder, S.; Mervic, M.; Lyall, R.; Levitzki, A.; Ullrich, A.; Zilberstein, A.; Schlessinger, J. EGF induces tyrosine phosphorylation of phospholipase C-II: A potential mechanism for EGF receptor signaling. Cell 1989, 57, 1101-1107. [CrossRef].
62. Lemmon, M. A.; Schlessinger, J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem. Sci. 1994, 19, 459-463. [CrossRef].
63. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501. [CrossRef] [PubMed].
64. Domin, J.; Waterfield, M. D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 1997, 410, 91-95. [CrossRef].
65. White, M. F. The IRS-signalling system: A network of docking proteins that mediate insulin action. Mol. Cell. Biochem. 1998, 182, 3-11. [CrossRef] [PubMed].
66. Vanhaesebroeck, B.; Stephens, L.; Hawkins, P. PI3K signalling: The path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 2012, 13, 195-203. [CrossRef] [PubMed].
67. Williams, R. L.; Katan, M. Structural views of phosphoinositide-specific phospholipase C: Signalling the way ahead. Structure 1996, 4, 1387-1394. [CrossRef].
68. Todderud, G.; Wahl, M. I.; Rhee, S. G.; Carpenter, G. Stimulation of phospholipase C-1 membrane association by epidermal growth factor. Science 1990, 249, 296-298. [CrossRef] [PubMed].
69. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992, 258, 607-614. [CrossRef] [PubMed].
70. Peters, K. G.; Marie, J.; Wilson, E.; Ives, H. E.; Escobedo, J.; Rosario, M. D.; Mirda, D.; Williams, L. T. Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature 1992, 358, 678-681. [CrossRef] [PubMed].
71. Nishibe, S.; Wahl, M. I.; Wedegaertner, P. B.; Kim, J.; Rhee, S. G.; Carpenter, G.; Kim, J. Selectivity of phospholipase C phosphorylation by the epidermal growth factor receptor, the insulin receptor, and their cytoplasmic domains. Proc. Natl. Acad. Sci. USA 1990, 87, 424-428. [CrossRef] [PubMed].
72. Moriya, S.; Kazlauskas, A.; Akimoto, K.; Hirai, S.; Mizuno, K.; Takenawa, T.; Fukui, Y.; Watanabe, Y.; Ozaki, S.; Ohno, S. Platelet-derived growth factor activates protein kinase C " through redundant and independent signaling pathways involving phospholipase C or phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. USA 1996, 93, 151-155. [CrossRef] [PubMed].
73. Larose, L.; Gish, G.; Shoelson, S.; Pawson, T. Identification of residues in the beta platelet-derived growth factor receptor that confer specificity for binding to phospholipase C-1. Oncogene 1993, 8, 2493-2499. [PubMed].
74. Akimoto, K.; Takahashi, R.; Moriya, S.; Nishioka, N.; Takayanagi, J.; Kimura, K.; Fukui, Y.; Osada, S. I.; Mizuno, K.; Hirai, S. I.; et al. EGF or PDGF receptors activate atypical pkclambda through phosphatidylinositol 3-kinase. EMBO J. 1996, 15, 788-798. [PubMed].
75. Brodie, C.; Bogi, K.; Acs, P.; Lazarovici, P.; Petrovics, G.; Anderson, W. B.; Blumberg, P. M. Protein kinase C-epsilon plays a role in neurite outgrowth in response to epidermal growth factor and nerve growth factor in PC12 cells. Cell Growth Differ. 1999, 10, 183-191. [PubMed].
76. Greco, S.; Muscella, A.; Elia, M. G.; Salvatore, P.; Storelli, C.; Mazzotta, A.; Manca, C.; Marsigliante, S. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J. Cell. Physiol. 2003, 196, 370-377. [CrossRef] [PubMed].
77. Burry, R. W. PKC activators (phorbol ester or bryostatin) stimulate outgrowth of ngf-dependent neurites in a subline of PC12 cells. J. Neurosc. Res. 1998, 53, 214-222. [CrossRef].
78. Welsh, J. B.; Gill, G. N.; Rosenfeld, M. G.; Wells, A. A negative feedback loop attenuates EGF-induced morphological changes. J. Cell Biol. 1991, 114, 533-543. [CrossRef] [PubMed].
79. Morrison, P.; Takishima, K.; Rosner, M. R. Role of threonine residues in regulation of the epidermal growth factor receptor by protein kinase C and mitogen-activated protein kinase. J. Biol. Chem. 1993, 268, 15536-15543. [PubMed].
80. Lund, K.; Lazar, C. S.; Chen, W.; Walsh, B.; Welsh, J.; Herbst, J.; Walton, G.; Rosenfeld, M.; Gill, G.; Wiley, H. Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. J. Biol. Chem. 1990, 265, 20517-20523. [PubMed].
81. Cochet, C.; Gill, G. N.; Meisenhelder, J.; Cooper, J. A.; Hunter, T. C-kinase phosphorylates the epidermal growth factor receptor and reduces its epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 1984, 259, 2553-2558. [PubMed].
82. Chen, P.; Xie, H.; Wells, A. Mitogenic signaling from the EGF receptor is attenuated by a phospholipase C-/protein kinase C feedback mechanism. Mol. Biol. Cell. 1996, 7, 871-881. [CrossRef] [PubMed].
83. Hackel, P. O.; Zwick, E.; Prenzel, N.; Ullrich, A. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 1999, 11, 184-189. [CrossRef].
84. Chen, P.; Xie, H.; Sekar, M. C.; Gupta, K.; Wells, A. Epidermal growth factor receptor-mediated cell motility: Phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J. Cell Biol. 1994, 127, 847-857. [CrossRef] [PubMed].
85. Kermorgant, S.; Zicha, D.; Parker, P. J. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of C-MET. J. Biol. Chem. 2003, 278, 28921-28929. [CrossRef] [PubMed].
86. Kermorgant, S.; Zicha, D.; Parker, P. J. PKC controls HGF-dependent C-MET traffic, signalling and cell migration. EMBO J. 2004, 23, 3721-3734. [CrossRef] [PubMed].
87. Besson, A.; Davy, A.; Robbins, S. M.; Yong, V. W. Differential activation of ERKS to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene 2001, 20, 7398-7407. [CrossRef] [PubMed].
88. Hashigasako, A.; Machide, M.; Nakamura, T.; Matsumoto, K.; Nakamura, T. Bi-directional regulation of SER-985 phosphorylation of C-met via protein kinase c and protein phosphatase 2a involves C-met activation and cellular responsiveness to hepatocyte growth factor. J. Biol. Chem. 2004, 279, 26445-26452. [CrossRef] [PubMed].
89. Dorsam, R. T.; Gutkind, J. S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 2007, 7, 79-94. [CrossRef] [PubMed].
90. Gilman, A. G. G proteins: Transducers of receptor-generated signals. Annu. Rev. Biochem. 1987, 56, 615-649. [CrossRef] [PubMed].
91. O'Hayre, M.; Vazquez-Prado, J.; Kufareva, I.; Stawiski, E. W.; Handel, T. M.; Seshagiri, S.; Gutkind, J. S. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer 2013, 13, 412-424. [CrossRef] [PubMed].
92. Neves, S. R.; Ram, P. T.; Iyengar, R. G protein pathways. Science 2002, 296, 1636-1639. [CrossRef] [PubMed].
93. Milligan, G.; Kostenis, E. Heterotrimeric G-proteins: A short history. Br. J. pharmacol. 2006, 147, S46-S55. [CrossRef] [PubMed].
94. Duprãl', D. J.; Robitaille, M.; Rebois, R. V.; Hãl'bert, T. E. The role of Gβγ subunits in the organization, assembly, and function of gpcr signaling complexes. Annu. Rev. pharmacol. Toxicol. 2009, 49, 31-56. [CrossRef] [PubMed].
95. Kolanus, W.; Seed, B. Integrins and inside-out signal transduction: Converging signals from PKC and PIP 3. Curr. Opin. Cell Biol. 1997, 9, 725-731. [CrossRef].
96. Parekh, D. B.; Ziegler, W.; Parker, P. J. Multiple pathways control protein kinase C phosphorylation. EMBO J. 2000, 19, 496-503. [CrossRef] [PubMed].
97. Disatnik, M. H.; Hernandez-Sotomayor, S. M.; Jones, G.; Carpenter, G.; Mochly-Rosen, D. Phospholipase C-gamma 1 binding to intracellular receptors for activated protein kinase C. Proc. Natl. Acad. Sci. USA 1994, 91, 559-563. [CrossRef] [PubMed].
98. Ginsberg, M. H.; Du, X.; Plow, E. F. Inside-out integrin signalling. Curr. Opin. Cell Biol. 1992, 4, 766-771. [CrossRef].
99. Ivashkiv, L. B. Cross-regulation of signaling by itam-associated receptors. Nat. Immunol. 2009, 10, 340-347. [CrossRef] [PubMed].
100. Woods, A.; Couchman, J. R. Protein kinase C involvement in focal adhesion formation. J. Cell Sci. 1992, 101, 277-290. [PubMed].
101. Griner, E. M.; Kazanietz, M. G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 2007, 7, 281-294. [CrossRef] [PubMed].
102. Ron, D.; Kazanietz, M. G. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999, 13, 1658-1676. [PubMed].
103. Barr, L. F.; Mabry, M.; Nelkin, B. D.; Tyler, G.; May, W. S.; Baylin, S. B. C-MYC gene-induced alterations in protein kinase C expression: A possible mechanism facilitating MYC-RAS gene complementation. Cancer Res. 1991, 51, 5514-5519. [PubMed].
104. Han, E. K.-H.; Cacace, A. M.; Sgambato, A.; Weinstein, I. B. Altered expression of cyclins and C-FOS in R6 cells that overproduce PKC." Carcinogenesis 1995, 16, 2423-2428. [CrossRef] [PubMed].
105. Da Rocha, A. B.; Mans, D. R. A.; Regner, A.; Schwartsmann, G. Targeting protein kinase C: New therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002, 7, 17-33. [CrossRef] [PubMed].
106. Lu, Z.; Hornia, A.; Jiang, Y. W.; Zang, Q.; Ohno, S.; Foster, D. A. Tumor promotion by depleting cells of protein kinase C delta. Mol. Cell. Biol. 1997, 17, 3418-3428. [PubMed].
107. Lu, Z.; Liu, D.; Hornia, A.; Devonish, W.; Pagano, M.; Foster, D. A. Activation of protein kinase C triggers its ubiquitination and degradation. Mol. Cell. Biol. 1998, 18, 839-845. [PubMed].
108. Gould, C. M.; Newton, A. C. The life and death of protein kinase c. Curr. Drug Targets 2008, 9, 614-625. [CrossRef] [PubMed].
109. Koivunen, J.; Aaltonen, V.; Peltonen, J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006, 235, 1-10. [CrossRef] [PubMed].
110. Langzam, L.; Koren, R.; Gal, R.; Kugel, V.; Paz, A.; Farkas, A.; Sampson, S. R. Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy. Am. J. Clin. Pathol. 2001, 116, 377-385. [CrossRef] [PubMed].
111. Varga, A.; Czifra, G.; Tallai, B.; Nemeth, T.; Kovacs, I.; Kovacs, L.; Biro, T. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur. Urol. 2004, 46, 462-465. [CrossRef] [PubMed].
112. Koren, R.; Ben Meir, D.; Langzam, L.; Dekel, Y.; Konichezky, M.; Baniel, J.; Livne, P. M.; Gal, R.; Sampson, S. R. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol. Rep. 2004, 11, 321-326. [CrossRef] [PubMed].
113. Fournier, D. B.; Chisamore, M.; Lurain, J. R.; Rademaker, A. W.; Jordan, V. C.; Tonetti, D. A. Protein kinase C + expression is inversely related to er status in endometrial carcinoma: Possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol. Oncol. 2001, 81, 366-372. [CrossRef] [PubMed].
114. Tsai, J. H.; Tsai, M. T.; Su, W. W.; Chen, Y. L.; Wu, T. T.; Hsieh, Y. S.; Huang, C. Y.; Yeh, K. T.; Liu, J. Y. Expression of protein kinase C alpha in biopsies and surgical specimens of human hepatocellular carcinoma. Chin. J. Physiol. 2005, 48, 139-143. [PubMed].
115. Neill, G. W.; Ghali, L. R.; Green, J. L.; Ikram, M. S.; Philpott, M. P.; Quinn, A. G. Loss of protein kinase calpha expression may enhance the tumorigenic potential of GLI1 in basal cell carcinoma. Cancer Res. 2003, 63, 4692-4697. [PubMed].
116. Kahl-Rainer, P.; Karner-Hanusch, J.; Weiss, W.; Marian, B. Five of six protein kinase C isoenzymes present in normal mucosa show reduced protein levels during tumor development in the human colon. Carcinogenesis 1994, 15, 779-782. [CrossRef] [PubMed].
117. Kerfoot, C.; Huang, W.; Rotenberg, S. A. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C α. J. Histochem. Cytochem. 2004, 52, 419-422. [CrossRef] [PubMed].
118. Ways, D. K.; Kukoly, C. A.; deVente, J.; Hooker, J. L.; Bryant, W. O.; Posekany, K. J.; Fletcher, D. J.; Cook, P. P.; Parker, P. J. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Investig. 1995, 95, 1906-1915. [CrossRef] [PubMed].
119. Lahn, M.; Kohler, G.; Sundell, K.; Su, C.; Li, S.; Paterson, B. M.; Bumol, T. F. Protein kinase C α expression in breast and ovarian cancer. Oncology 2004, 67, 1-10. [CrossRef] [PubMed].
120. Koivunen, J.; Aaltonen, V.; Koskela, S.; Lehenkari, P.; Laato, M.; Peltonen, J. Protein kinase C α/β inhibitor GO6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 2004, 64, 5693-5701. [CrossRef] [PubMed].
121. Masur, K.; Lang, K.; Niggemann, B.; Zanker, K. S.; Entschladen, F. High PKC β and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol. Biol. Cell 2001, 12, 1973-1982. [CrossRef] [PubMed].
122. Nakashima, S. Protein kinase C alpha (PKC+): Regulation and biological function. J. Biochem. 2002, 132, 669-675. [CrossRef] [PubMed].
123. Ng, T.; Shima, D.; Squire, A.; Bastiaens, P. I.; Gschmeissner, S.; Humphries, M. J.; Parker, P. J. Pkcalpha regulates +1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J. 1999, 18, 3909-3923. [CrossRef] [PubMed].
124. Rabinovitz, I.; Toker, A.; Mercurio, A. M. Protein kinase C-dependent mobilization of the α6β4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. J. Cell. Biol. 1999, 146, 1147-1160. [CrossRef] [PubMed].
125. Ainsworth, P.; Winstanley, J.; Pearson, J.; Bishop, H.; Garrod, D. Protein kinase C α expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma. Eur. J. Cancer 2004, 40, 2269-2273. [CrossRef] [PubMed].
126. Gilhooly, E. M.; Morse-Gaudio, M.; Bianchi, L.; Reinhart, L.; Rose, D. P.; Connolly, J. M.; Reed, J. A.; Albino, A. P. Loss of expression of protein kinase C α is a common phenomenon in human malignant melanoma: A result of transformation or differentiation? Melanoma Res. 2001, 11, 355-369. [CrossRef] [PubMed].
127. Li, H.; Weinstein, I. B. Protein kinase c beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res. 2006, 66, 11399-11408. [CrossRef] [PubMed].
128. Urtreger, A. J.; Kazanietz, M. G.; Bal de Kier Joffãl, E. D. Contribution of individual PKC isoforms to breast cancer progression. IUBMB Life 2012, 64, 18-26. [CrossRef] [PubMed].
129. Grossoni, V. C.; Todaro, L. B.; Kazanietz, M. G.; de Kier Joffãl', E. D. B.; Urtreger, A. J. Opposite effects of protein kinase c beta1 (PKC+1) and PKC" in the metastatic potential of a breast cancer murine model. Breast Cancer Res. Treat. 2009, 118, 469-480. [CrossRef] [PubMed].
130. Gãűkmen-Polar, Y.; Murray, N. R.; Velasco, M. A.; Gatalica, Z.; Fields, A. P. Elevated protein kinase C αII is an early promotive event in colon carcinogenesis. Cancer Res. 2001, 61, 1375-1381. [PubMed].
131. Graff, J. R.; McNulty, A. M.; Hanna, K. R.; Konicek, B. W.; Lynch, R. L.; Bailey, S. N.; Banks, C.; Capen, A.; Goode, R.; Lewis, J. E. The protein kinase Cα-selective inhibitor, enzastaurin (ly317615. HCL), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005, 65, 7462-7469. [CrossRef] [PubMed].
132. Lee, K.-W.; Kim, S. G.; Kim, H.-P.; Kwon, E.; You, J.; Choi, H.-J.; Park, J.-H.; Kang, B.-C.; Im, S.-A.; Kim, T.-Y. Enzastaurin, a protein kinase C α inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 2008, 68, 1916-1926. [CrossRef] [PubMed].
133. Yoshiji, H.; Kuriyama, S.; Ways, D. K.; Yoshii, J.; Miyamoto, Y.; Kawata, M.; Ikenaka, Y.; Tsujinoue, H.; Nakatani, T.; Shibuya, M. Protein kinase c lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 1999, 59, 4413-4418. [PubMed].
134. Xia, P.; Aiello, L. P.; Ishii, H.; Jiang, Z. Y.; Park, D. J.; Robinson, G. S.; Takagi, H.; Newsome, W. P.; Jirousek, M. R.; King, G. L. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Investig. 1996, 98, 2018-2026. [CrossRef] [PubMed].
135. Kamimura, K.; Hojo, H.; Abe, M. Characterization of expression of protein kinase c isozymes in human b-cell lymphoma: Relationship between its expression and prognosis. Pathol. Int. 2004, 54, 224-230. [CrossRef] [PubMed].
136. Mazzoni, E.; Adam, A.; de Kier Joffe, E. B.; Aguirre-Ghiso, J. A. Immortalized mammary epithelial cells overexpressing protein kinase C acquire a malignant phenotype and become tumorigenic in vivo. Mol. Cancer Res. 2003, 1, 776-787. [PubMed].
137. Swannie, H.; Kaye, S. Protein kinase c inhibitors. Curr. Oncol. Rep. 2002, 4, 37-46. [CrossRef] [PubMed].
138. Gray, M. O.; Karliner, J. S.; Mochly-Rosen, D. A selective "-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J. Biol. Chem. 1997, 272, 30945-30951. [CrossRef] [PubMed].
139. Leskow, F. C.; Krasnapolski, M. A.; Urtreger, A. J. The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients. Curr. Pharm. Biotechnol. 2011, 12, 1961-1973. [CrossRef] [PubMed].
140. Andrejauskas-Buchdunger, E.; Regenass, U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 1992, 52, 5353-5358. [PubMed].
141. Tenzer, A.; Zingg, D.; Rocha, S.; Hemmings, B.; Fabbro, D.; Glanzmann, C.; Schubiger, P. A.; Bodis, S.; Pruschy, M. The phosphatidylinositide 3Êź-kinase/akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase c. Cancer Res. 2001, 61, 8203-8210. [PubMed].
142. Faul, M. M.; Gillig, J. R.; Jirousek, M. R.; Ballas, L. M.; Schotten, T.; Kahl, A.; Mohr, M. Acyclic n-(azacycloalkyl) bisindolylmaleimides: Isozyme selective inhibitors of PKCα. Bioorg. Med. Chem. Lett. 2003, 13, 1857-1859. [CrossRef].
143. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; et al. In vivo antitumor activity of su11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9, 327-337. [PubMed].
144. Kreisl, T. N.; Kotliarova, S.; Butman, J. A.; Albert, P. S.; Kim, L.; Musib, L.; Thornton, D.; Fine, H. A. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-oncology 2010, 12, 181-189. [CrossRef] [PubMed].
145. Workman, P.; Kaye, S. B.; Schwartsmann, G. Laboratory and phase I studies of new cancer drugs. Curr. Opin. Oncol. 1992, 4, 1065-1072. [CrossRef] [PubMed].
146. Pavlick, A.; Wu, J.; Roberts, J.; Rosenthal, M.; Hamilton, A.; Wadler, S.; Farrell, K.; Carr, M.; Fry, D.; Murgo, A.; et al. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother. Pharmacol. 2009, 64, 803-810. [CrossRef] [PubMed].
147. Souroujon, M. C.; Mochly-Rosen, D. Peptide modulators of protein-protein interactions in intracellular signaling. Nat. Biotechnol. 1998, 16, 919-924. [CrossRef] [PubMed].
148. Kim, J.; Choi, Y.-L.; Vallentin, A.; Hunrichs, B. S.; Hellerstein, M. K.; Peehl, D. M.; Mochly-Rosen, D. Centrosomal PKCαII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 2008, 68, 6831-6839. [CrossRef] [PubMed].
149. Ferreira, J. C.; Koyanagi, T.; Palaniyandi, S. S.; Fajardo, G.; Churchill, E. N.; Budas, G.; Disatnik, M.-H.; Bernstein, D.; Brum, P. C.; Mochly-Rosen, D. Pharmacological inhibition of-IIPKC is cardioprotective in late-stage hypertrophy. J. Mol. Cell. Cardiol. 2011, 51, 980-987. [CrossRef] [PubMed].
150. Castagna, M.; Takai, Y.; Kaibuchi, K.; Sano, K.; Kikkawa, U.; Nishizuka, Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 1982, 257, 7847-7851. [PubMed].
151. O'Brian, C. A.; Liskamp, R. M.; Solomon, D. H.; Weinstein, I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985, 45, 2462-2465. [PubMed].
152. Kikkawa, U.; Takai, Y.; Tanaka, Y.; Miyake, R.; Nishizuka, Y. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J. Biol. Chem. 1983, 258, 11442-11445. [PubMed].
153. Blobe, G. C.; Obeid, L. M.; Hannun, Y. A. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev. 1994, 13, 411-431. [CrossRef] [PubMed].
154. Reyland, M. Protein kinase cdelta and apoptosis. Biochem. Soc. Trans. 2007, 35, 1001-04. [PubMed].
155. Symonds, J. M.; Ohm, A. M.; Carter, C. J.; Heasley, L. E.; Boyle, T. A.; Franklin, W. A.; Reyland, M. E. Protein kinase C α is a downstream effector of oncogenic k-ras in lung tumors. Cancer Res. 2011, 71, 2087-2097. [CrossRef] [PubMed].
156. Mauro, L. V.; Grossoni, V. C.; Urtreger, A. J.; Yang, C.; Colombo, L. L.; Morandi, A.; Pallotta, M. G.; Kazanietz, M. G.; de Kier Joffãl', E. D. B.; Puricelli, L. L. PKC delta (PKCα) promotes tumoral progression of human ductal pancreatic cancer. Pancreas 2010, 39, e31-e41. [CrossRef] [PubMed].
157. Luna-Ulloa, L. B.; Hernandez-Maqueda, J. G.; Santoyo-Ramos, P.; Castaneda-Patlan, M. C.; Robles-Flores, M. Protein kinase C α is a positive modulator of canonical wnt signaling pathway in tumoral colon cell lines. Carcinogenesis 2011, 32, 1615-1624. [CrossRef] [PubMed].
158. Ma, L.; Tao, Y.; Duran, A.; Llado, V.; Galvez, A.; Barger, J. F.; Castilla, E. A.; Chen, J.; Yajima, T.; Porollo, A. Control of nutrient stress-induced metabolic reprogramming by PKCα in tumorigenesis. Cell 2013, 152, 599-611. [CrossRef] [PubMed].
159. Mackay, H. J.; Twelves, C. J. Targeting the protein kinase c family: Are we there yet? Nat. Rev. Cancer 2007, 7, 554-562. [CrossRef] [PubMed].
160. Antal, C. E.; Hudson, A. M.; Kang, E.; Zanca, C.; Wirth, C.; Stephenson, N. L.; Trotter, E. W.; Gallegos, L. L.; Miller, C. J.; Furnari, F. B. Cancer-associated protein kinase c mutations reveal kinase's role as tumor suppressor. Cell 2015, 160, 489-502. [CrossRef] [PubMed].
161. Zhang, L.; Cao, F.; Wang, Y.; Meng, F.; Zhang, Y.; Zhong, D.; Zhou, Q. The Protein Kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: Meta-analysis of randomized controlled trials. Clin. Trans. Oncol. 2015, 17, 371-377. [CrossRef] [PubMed].